



**Have You Been Diagnosed
with Covid-19?**

**Monoclonal Antibody
Treatment May Be Right
for You!**

**Call the Covid-19
Treatment Hotline
(409) 550-2536**



**Covid-19
Treatment Hotline
(409) 550-2536**

**REGEN-COV for COVID-19:
Emergency Use Authorization (EUA)**

REGEN-COV is an investigational medicine that may benefit certain people with COVID-19 and may help prevent certain people who have been exposed to someone who is infected with SARS-CoV-2 from getting SARS-CoV-2 infection, or may prevent certain people who are at high risk of exposure to someone who is infected with SARS-CoV-2 from getting SARS-CoV-2 infection.

It is still being studied and there is limited information known about its safety and effectiveness. The U.S. Food and Drug Administration (FDA) has authorized the emergency use of REGEN-COV for the treatment of COVID-19 and the post-exposure prevention of COVID-19 under an EUA.

WHAT IS MONOCLONAL ANTIBODY TREATMENT?

As defined by the [Food and Drug Administration](#) (FDA), which issued Emergency Use Authorization (EUA) of the certain treatments last year, monoclonal antibodies are "laboratory-produced molecules that act as substitute antibodies that can restore, enhance or mimic the immune system's attack on cells. Monoclonal antibodies for COVID-19 may block the virus that causes COVID-19 from attaching to human cells, making it more difficult for the virus to reproduce and cause harm. Monoclonal antibodies may also neutralize a virus."

WHAT DOES IT MEAN TO BE HIGH RISK?

The following medical conditions or other factors may place adults and adolescent patients (age 12-17 years and weighing at least 88 pounds [40 kg]) at higher risk for progression to severe COVID-19:

- Older age (for example, age ≥ 65 years of age)

- Obesity or being overweight (for example, BMI >25 kg/m², or if age 12-17, have BMI ≥ 85 th percentile for their age and gender based on [CDC growth charts](#))
- Pregnancy
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease) or hypertension
- Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
- Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19))

Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and authorization of REGEN-COV under the EUA is not limited to the medical conditions or factors listed above.

For additional information on medical conditions and factors associated with increased risk for progression to severe COVID-19, see the [CDC website](#).